Mode
Text Size
Log in / Sign up
Phase 4 Completed N=99 Randomized Double-blind Treatment

Pre-medication With Alfentanil vs Placebo During ECT

Blood Pressure · Electroconvulsive Therapy
Source: ClinicalTrials.gov NCT03359395 ↗
Enrolled (actual)
99
Serious AEs
1.2%
Results posted
Jul 2021
Primary outcomePrimary: Systolic Blood Pressure Change — 22.011; 38.908 mmHg
◆ Published Evidence
Emerging
3citations · ~1 / year
Alfentanil Pretreatment for Electroconvulsive Therapy-Associated Hemodynamic Lability: A Prospective Randomized Crossover Trial.
The journal of ECT · 2023 · Likely link

Summary

Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized with the administration of alfentanil as part of their anesthetic regimen. This study proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved drug used on a daily basis by anesthesiologists on other surgeries so this is not a new indication.

Linked Publications

  • Alfentanil Pretreatment for Electroconvulsive Therapy-Associated Hemodynamic Lability: A Prospective Randomized Crossover Trial.
    The journal of ECT · 2023 · 3 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Systolic Blood Pressure Change
22.011; 38.908
SECONDARY
Diastolic Blood Pressure Change
15.26; 23.34
SECONDARY
Heart Rate
SECONDARY
Maximum Heart Rate
44.33; 49.66
SECONDARY
Minimum Heart Rate
12.74; 7.08
SECONDARY
Doses of Antihypertensive Medication
SECONDARY
Time to Return of Spontaneous Ventilation
8.17; 7.25
SECONDARY
Total Time Subject Spent In-Room
17.51; 16.43
SECONDARY
Severity of Headache in the Post Anesthesia Care Unit
2; 2.467
SECONDARY
Satisfaction With the Anesthetic Post-procedure
8; 8.033

Eligibility Criteria

Inclusion Criteria

  • Age > /=18 years
  • Males or females
  • Anticipating electroconvulsive therapy to treat refractory depressive disorder

Exclusion Criteria

  • Under the age of 18
  • Allergy to alfentanil
  • Allergy to other standard anesthetic medications utilized in the course of ECT (glycopyrrolate, methohexital, and succinylcholine)
  • History of malignant hyperthermia
  • History of severe airway obstruction, bronchospasm or laryngospasm
  • History of recent myocardial infarction, ventricular arrhythmia
  • Adverse reaction to ECT requiring premedication with lidocaine or atropine
  • Non-English speaking
  • Patients unable to consent for themselves
  • Current pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03359395) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search